New book by Larry Connors Click here Improve your trading - See how
You see, our newsletter is truly different from the rest. We provide lots of content in our mailers with tons of information that the average person can understand. We don't waste time trying to uncover ideas that might move a wimpy 5-10% in a few months like most other guys. No, we're looking at stocks that can explode 50+% or more in a matter of days! Join Here!
Today's news alerts include: Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier
Roche to fund evaluation of Raptor's proprietary NeuroTrans(TM) technology
NOVATO, Calif., June 9, 2009 -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that it has entered a collaboration and licensing agreement with Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) to evaluate therapeutic delivery across the blood-brain barrier, ("BBB") starting with Raptor's proprietary NeuroTrans(TM) BBB transporter platform. Under terms of the agreement, Roche will fund studies of select molecules attached to Raptor's proprietary NeuroTrans(TM), a derivative of the receptor-associated protein ("RAP"). The agreement provides Roche with an exclusive worldwide license to NeuroTrans(TM) for use in the delivery of diagnostic and therapeutic molecules across the BBB.
(Logo: http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO )
Scientists at Raptor and Roche will actively collaborate on the project. Raptor will receive an initial upfront fee for the collaboration to cover its portion of the initial studies, along with development milestone payments and royalties in exchange for the licensing of NeuroTrans(TM).
Todd C. Zankel, Ph.D., Chief Scientific Officer and co-founder of Raptor, stated, "We are excited to be collaborating with Roche, a world leader in pharmaceutical research. We believe that by combining our knowledge of the work done in the area of BBB transport and the resources of Roche, our collaboration is well positioned to make significant progress in a critical and challenging area in medical research."
Crossing the BBB remains a major obstacle to effectively treating most neurological disorders. While medical research has identified hundreds of potential therapeutic compounds that might be highly effective in treating devastating neurodegenerative diseases, including Alzheimer's, Parkinson's, and Huntington's Disease, the majority of these compounds do not cross the BBB by themselves. So they cannot get to where they need to go to be effective drugs. The challenge of finding a means to deliver these compounds to the brain has resulted in an intensive search for "BBB transporter molecules" that could be attached to these potential therapeutics and, following intravenous administration, deliver the drug to the brain.
"Our collaboration with Roche will enable us to further the development of Raptor's NeuroTrans(TM) BBB transporter molecules, in conjunction with Roche's proprietary therapeutic molecules, to potentially deliver these compounds in therapeutic quantities across the BBB following intravenous administration" said Christopher Starr, Ph.D. CEO of Raptor. "It is our hope that this collaboration, which will leverage the knowledge and expertise of Dr. Zankel and his group here at Raptor, coupled with the ongoing research of the scientists at Roche, will bring us an increased understanding of the most effective means to transport therapeutic molecules across the BBB, in order to more effectively treat these devastating neurodegenerative diseases."
About NeuroTrans(TM)
NeuroTrans(TM) is Raptor's proprietary receptor-associated protein ("RAP")-based technology program designed to deliver therapeutics across the blood-brain barrier ("BBB"), with the potential to provide safer, less intrusive, and more effective therapies to treat a wide variety of brain disorders. Preclinical studies indicate that radio-labeled NeuroTrans(TM) crosses the BBB through transcytosis, or the selective receptor-mediated transport of peptides and large proteins across the endothelial membrane in the BBB. NeuroTrans(TM) has also been conjugated to a variety of protein drugs, including enzymes and growth factors, without interfering with their therapeutic functions.
Raptor recently announced that the United States Patent and Trademark Office ("USPTO") has issued two Notices of Allowance for U.S. Patent Application Nos. 10/812,849 and 11/202,566, titled "Methods of increasing delivery of active agents to brain comprising administering receptor-associated protein ("RAP") fragments conjugated to active agents".
About Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. ("Raptor") is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Raptor focuses on underserved patient populations where it can have the greatest potential impact. Raptor currently has product candidates in clinical development to treat nephropathic cystinosis, non-alcoholic steatohepatitis ("NASH"), Huntington's Disease ("HD"), and aldehyde dehydrogenase ("ALDH2") deficiency.
Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins that are designed to target cancer, neurodegenerative disorders and infectious diseases.
For additional information, please visit www.raptorpharma.com.
About PicksThatMove.com
www.picksthatmove.com team of excellence strives to find undervalued, good momentum stock plays. We provide financial and investor relations services for small to mid-cap stocks with weekly and special newsletters to keep you informed of the latest movers. Unlike other sites, we explore, research, and understand all aspects of a company. We only recommend companies we feel has the potential for future higher valuations. Our seasoned research team is always looking for the next Xtreme Pick to send to you.
www.picksthatmove.com is a leading stock website that provides free daily alerts on stocks that are moving up. www.picksthatmove.com also tracks small cap stocks that are on the brink of exploding. We also feature companies on our website with research report, analysis, and newsletters. To feature a company on our web site please contact us at Info@picksthatmove.com
www.picksthatmove.com is an independent electronic publication that provides information on selected publicly traded companies. www.picksthatmove.com is not a registered investment advisor or broker-dealer. www.picksthatmove.com affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.
CONTACT: PicksThatMove.com e-mail: Info@picksthatmove.com WWW: http://www.picksthatmove.com
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
